Literature DB >> 17268152

[Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine].

Jun Kunisawa1, Masashi Gohda, Hiroshi Kiyono.   

Abstract

The mucosal immune system acts as the first line of defense against microbial infection through a dynamic immune network based on innate and acquired mucosal immunity. To prevent infectious diseases, it is pivotal to develop effective mucosal vaccines that can induce both mucosal and systemic immune responses, especially secretory IgA (S-IgA) and plasma IgG, against pathogens. Recent advances in medical and biomolecular engineering technology and progress in cellular and molecular immunology and infectious diseases have made it possible to develop versatile mucosal vaccine systems. In particular, mucosal vaccines have become more attractive due to recent development and adaptation of new types of drug delivery systems not only for the protection of antigens from the harsh conditions of the mucosal environment but also for effective antigen delivery to mucosa-associated lymphoid tissues such as Peyer's patches and nasopharynx-associated lymphoid tissue, the initiation site for the induction of the antigen-specific immune response. In this review, we shed light on the dynamics of the mucosal immune system and recent advances toward the development of prospective mucosal antigen delivery systems for vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268152     DOI: 10.1248/yakushi.127.319

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  6 in total

1.  Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.

Authors:  Rui Tada; Shoko Muto; Tomoko Iwata; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2017-01-26

2.  Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation against Streptococcus pneumoniae Infections in Mice.

Authors:  Rui Tada; Hidehiko Suzuki; Miki Ogasawara; Daisuke Yamanaka; Yoshiyuki Adachi; Jun Kunisawa; Yoichi Negishi
Journal:  Pharmaceutics       Date:  2021-04-20       Impact factor: 6.321

3.  Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice.

Authors:  Rui Tada; Miki Ogasawara; Daisuke Yamanaka; Yasuhiro Sakurai; Yoichi Negishi; Hiroshi Kiyono; Naohito Ohno; Jun Kunisawa; Yukihiko Aramaki
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

4.  Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes.

Authors:  Rui Tada; Emi Honjo; Shoko Muto; Noriko Takayama; Hiroshi Kiyono; Jun Kunisawa; Yoichi Negishi
Journal:  Membranes (Basel)       Date:  2022-06-20

5.  Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.

Authors:  Rui Tada; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2018-07-13

6.  Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity.

Authors:  Rui Tada; Akihiro Ohshima; Yuya Tanazawa; Akari Ohmi; Saeko Takahashi; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki; Yoichi Negishi
Journal:  Vaccines (Basel)       Date:  2019-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.